Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.

Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME.

Clin Chem. 2010 Sep;56(9):1492-5. doi: 10.1373/clinchem.2010.143297. Epub 2010 Jun 25.

2.

Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.

Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S.

Sci Transl Med. 2010 Mar 31;2(25):25ra23. doi: 10.1126/scitranslmed.3000403.

3.

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS.

Nat Med. 2009 May;15(5):559-65. doi: 10.1038/nm.1944. Epub 2009 Apr 12. Erratum in: Nat Med. 2009 Jul;15(7):819.

4.

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS.

Cancer Res. 2009 Apr 1;69(7):2912-8. doi: 10.1158/0008-5472.CAN-08-3667.

5.

Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.

Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M, Scher HI.

Clin Cancer Res. 2009 Mar 15;15(6):2091-7. doi: 10.1158/1078-0432.CCR-08-2036. Epub 2009 Mar 10.

6.

Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer.

Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, Bertz S, Harzmann R, Klein CA.

J Clin Oncol. 2009 Apr 1;27(10):1549-56. doi: 10.1200/JCO.2008.17.0563. Epub 2009 Feb 23.

PMID:
19237635
7.

Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.

Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH, Zucker S, Simko J, Chen WT, Rosenberg J.

Cancer Lett. 2009 May 18;277(2):164-73. doi: 10.1016/j.canlet.2008.12.007. Epub 2009 Jan 21.

PMID:
19162393
8.

Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.

Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA.

J Natl Cancer Inst. 2009 Jan 7;101(1):61-6. doi: 10.1093/jnci/djn419. Epub 2008 Dec 30.

9.

Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR.

Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, Gratama JW, Sleijfer S, Foekens JA.

Breast Cancer Res Treat. 2009 Dec;118(3):455-68. doi: 10.1007/s10549-008-0290-0. Epub 2008 Dec 30.

PMID:
19115104
10.

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D.

Clin Cancer Res. 2008 Oct 1;14(19):6302-9. doi: 10.1158/1078-0432.CCR-08-0872. Erratum in: Clin Cancer Res. 2009 Feb 15;15(4):1506.

11.

Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.

Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, Ewing CM, Dalrymple S, Turner AR, Sun J, Isaacs JT, Chang BL, Zheng SL, Isaacs WB, Xu J.

Neoplasia. 2008 Aug;10(8):897-907.

12.

Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.

Holcomb IN, Grove DI, Kinnunen M, Friedman CL, Gallaher IS, Morgan TM, Sather CL, Delrow JJ, Nelson PS, Lange PH, Ellis WJ, True LD, Young JM, Hsu L, Trask BJ, Vessella RL.

Cancer Res. 2008 Jul 15;68(14):5599-608. doi: 10.1158/0008-5472.CAN-08-0812.

13.

Detection, clinical relevance and specific biological properties of disseminating tumour cells.

Pantel K, Brakenhoff RH, Brandt B.

Nat Rev Cancer. 2008 May;8(5):329-40. doi: 10.1038/nrc2375. Review.

PMID:
18404148
14.

High-resolution array comparative genomic hybridization of single micrometastatic tumor cells.

Fuhrmann C, Schmidt-Kittler O, Stoecklein NH, Petat-Dutter K, Vay C, Bockler K, Reinhardt R, Ragg T, Klein CA.

Nucleic Acids Res. 2008 Apr;36(7):e39. doi: 10.1093/nar/gkn101. Epub 2008 Mar 15.

16.

Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.

Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Dec 1;13(23):7053-8.

17.

Challenges in array comparative genomic hybridization for the analysis of cancer samples.

Nowak NJ, Miecznikowski J, Moore SR, Gaile D, Bobadilla D, Smith DD, Kernstine K, Forman SJ, Mhawech-Fauceglia P, Reid M, Stoler D, Loree T, Rigual N, Sullivan M, Weiss LM, Hicks D, Slovak ML.

Genet Med. 2007 Sep;9(9):585-95.

PMID:
17873646
18.

DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies.

Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, Xu J.

Prostate. 2007 May 15;67(7):692-700.

PMID:
17342750
19.

High resolution array-CGH analysis of single cells.

Fiegler H, Geigl JB, Langer S, Rigler D, Porter K, Unger K, Carter NP, Speicher MR.

Nucleic Acids Res. 2007;35(3):e15. Epub 2006 Dec 18.

20.

Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?

Cristofanilli M, Mendelsohn J.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17073-4. Epub 2006 Nov 7. No abstract available.

Supplemental Content

Support Center